The MEVPRO-2 Phase 3 Trial of Mevrometostat plus Enzalutamide in ARPI-Naive mCRPC - Neal Shore
Neal Shore
Neal Shore describes the MEVPRO-2 trial design, a 900-patient double-blind randomized study of mevrometostat 875 mg twice daily with food plus enzalutamide versus enzalutamide alone in ARPI-naive mCRPC patients.
Translational Insights for Cretostimogene Grenadenorepvec for BCG-Naïve Bladder Cancer - Trinity Bivalacqua
Trinity Bivalacqua
Trinity Bivalacqua discusses the translational data from CORE-008 Cohort A, examining cretostimogene grenadenorepvec in high-risk BCG-naive NMIBC with a focus on the five-step versus two-step administration protocol.
